project id: TCGA-PRAD; case submitter id: TCGA-J9-A8CM; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.9; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.74; rna integrity number: 8.4; age at index: 66; days to birth: -24118; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1947; age at diagnosis: 24118; ajcc clinical m: M0; ajcc clinical t: T2c; ajcc pathologic n: N1; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 463.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 238; initial weight: 230.0; sample id: bb8d2190-663a-4952-b310-44a115b39e97; sample submitter id: TCGA-J9-A8CM-01A; portion id: 5002dd35-cc51-4bb6-b7c6-8d4c5b37677e; portion submitter id: TCGA-J9-A8CM-01A-11; slide id: 05046e64-a6e1-4be9-9c7e-55ca7116c193; slide submitter id: TCGA-J9-A8CM-01A-01-TS1; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 20.0; percent tumor cells: 80.0; percent tumor nuclei: 90.0; section location: TOP;